— Know what they know.
Not Investment Advice
Also trades as: EIGRQ (OTC) · $vol 0M

EIGR NASDAQ

Eiger BioPharmaceuticals, Inc.
1W: -35.7% 1M: +0.0% 3M: -70.0% 1Y: -95.0% 3Y: -99.3% 5Y: -99.5%
$1.73
Last traded 2025-06-17 — delisted
NASDAQ · Healthcare · Biotechnology · $2.6M mcap · 1M float · 10.37% daily turnover

Balance Sheet Trends

Total Assets
$39M -67.7% ▼
5Y CAGR: -17.6%
Total Liabilities
$53M -17.8% ▼
5Y CAGR: +8.2%
Shareholders Equity
-$14M -126.1% ▼
Cash & Investments
$25M -74.3% ▼
5Y CAGR: -24.0%
Total Debt
$41M +2.5% ▲
5Y CAGR: +10.0%
Net Debt
$16M +9.5% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$39M$29M$22M$26M$25M
Short-Term Investments$56M$100M$67M$73M$0
Cash & ST Investments$95M$129M$89M$99M$25M
Net Receivables$0$0$3M$2M$2M
Inventory$0$93K$3M$3M$2M
Other Current Assets$5M$1M$1M$2M$1M
Total Current Assets$100M$138M$103M$118M$38M
Property, Plant & Equip.$2M$2M$1M$1M$627K
Goodwill & Intangibles$0$0-$137K$0$0
Long-Term Investments$0$0$17M$0$0
Other Non-Current Assets$3M$4M$5M$1M$360K
Total Non-Current Assets$5M$6M$23M$3M$987K
Total Assets$105M$144M$126M$120M$39M
— Liabilities —
Accounts Payable$6M$5M$8M$9M$2M
Short-Term Debt$534K$582K$8M$0$41M
Deferred Revenue$0$0$2M$1M$0
Other Current Liabilities$1M$3M$5M$8M$5M
Total Current Liabilities$17M$17M$30M$25M$53M
Long-Term Debt$30M$0$24M$40M$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$32M$32M$24M$40M$0
Total Liabilities$49M$49M$54M$65M$53M
— Equity —
Common Stock$24K$34K$35K$44K$1K
Retained Earnings-$241M-$306M-$340M-$437M-$512M
Accumulated OCI$42K-$8K-$149K-$300K-$169K
Total Stockholders Equity$56M$95M$72M$55M-$14M
Total Liabilities & Equity$105M$144M$126M$120M$39M
— Key Metrics —
Total Debt$32M$33M$33M$40M$41M
Net Debt-$7M$4M$10M$14M$16M
Total Investments$56M$100M$84M$73M$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms